Iovance reports Q2 2025 earnings: $60M revenue, appoints new CFO, extends cash runway into Q4 2026

IOVANCE BIOTHERAPEUTICS, INC.

2025-Q2 EPS reported -$0.69 revenue$109,276,000

Q2 2025 total product revenue $60.0M (Amtagvi $54.1M, Proleukin $5.9M), net loss $111.7M.
Reiterated FY2025 total product revenue guidance of $250M-$300M.
Appointed Corleen Roche as CFO, effective after Q2 10-Q filing, replacing Matthew Rosinack.
Strategic restructuring reduces workforce by 19%, generating over $100M annual savings, extending cash runway into Q4 2026.
Over 100 patients treated with Amtagvi in Q2; network includes over 80 ATCs across 35 states.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.